Biocept (NASDAQ:BIOC) Coverage Initiated by Analysts at

Stock analysts at initiated coverage on shares of Biocept (NASDAQ:BIOCGet Rating) in a note issued to investors on Sunday. The firm set a “hold” rating on the medical research company’s stock.

Separately, Brookline Capital Management lowered Biocept from a “buy” rating to a “hold” rating in a report on Friday, January 6th.

Biocept Stock Performance

Shares of Biocept stock opened at $0.24 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 5.13 and a quick ratio of 4.86. The business has a 50-day simple moving average of $0.51 and a 200 day simple moving average of $0.68. The firm has a market capitalization of $4.02 million, a price-to-earnings ratio of -0.24 and a beta of 1.01. Biocept has a one year low of $0.24 and a one year high of $2.43.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Biocept stock. Millennium Management LLC bought a new stake in shares of Biocept, Inc. (NASDAQ:BIOCGet Rating) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 103,124 shares of the medical research company’s stock, valued at approximately $97,000. Millennium Management LLC owned about 0.61% of Biocept as of its most recent filing with the Securities & Exchange Commission. 10.04% of the stock is owned by institutional investors.

Biocept Company Profile

(Get Rating)

Biocept, Inc is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample.

Featured Articles

Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with's FREE daily email newsletter.